Abstract: A method for preparing d,1-5-methyltetrahydrofolic acid and the salts thereof of the formula: ##STR1## wherein X is hydrogen, an alkaline metal or alkaline earth metal; by reduction of folic acid with sodium borohydride followed by the methylation of the tetrahydrofolic acid thus obtained with aqueous solutions of formaldehye and sodium borohydride in an inert atmosphere.

Abstract: This invention relates to new stable sulpho-adenosyl-L-methionine (SAMe) salts and the relative production process.Said salts have the following general formula:SAMe.nR(O).sub.m (SO.sub.3 H).sub.p (I)where m can be zero or 1; n is 1.5 when p is 2, and is 3 when p is 1; R is chosen from the group consisting of alkyl, phenylalkyl and carboxyalkyl, in which the linear or branched alkyl chain contains from 8 to 18 carbon atoms.In particular, the salts according to the present invention are SAMe salts of sulphonic acids, or of sulphuric acid esters, or of dioctylsulphosuccinic acid, which fall within formula (I).The process for producing said salts consists of: a) enriching the starting yeast with SAMe; b) lysing the cells and recovering an aqueous solution rich in SAMe (cell lysate); c) purifying the lysate by ultrafiltration; d) precipitating the SAMe by treatment with one of the aforesaid acids or esters; e) separating the precipitated product, washing it and drying it under vacuum.

Abstract: A method for preparing d,1-5-methyltetrahydrofolic acid and the salts thereof of the formula: ##STR1## wherein X is hydrogen, an alkaline metal or alkaline earth metal; by reduction of folic acid with sodium borohydride followed by the methylation of the tetrahydrofolic acid thus obtained with aqueous solutions of formaldehyde and sodium borohydride in an inert atmosphere.

Abstract: The invention discloses injectable therapeutic compositions containing stable S-adenosyl-L-methionine (SAMe) salts as an active ingredient. Injectable therapeutic compositions which permit large doses of SAMe to be administered by injection, at physiological pH having excellent tolerability has been achieved by administering SAMe salts in an aqueous solution which is adjusted to a pH of between 5 and 8.5 containing an amino acid and an alkaline base in critical proportions.

Abstract: Pteridines of general formula (I): ##STR1## in which Y and Z, which can be identical or different, are hydrogen, OH or NH.sub.2, and X.sub.1 and X.sub.2, which can be identical or different, are hydrogen, OH, C.sub.1 -C.sub.4 alkyl, phenyl, hydroxymethyl or carboxyl, for the preparation of pharmaceutical compositions for treating cognitive pathologies characterized by memory and vigilance disturbances, such as senile dementia of Alzheimer type, multiinfarctual dementia, metabolic encephalopathies, Korsakoff's syndrome, and the consequences of the abuse of certain therapies such as anxiolytic and neuroleptic.

Abstract: New salts of 5'-methylthio-5'-deoxyadenosine (MTA) with long-alkyl chain sulphonic acids, which possess central and peripheral vaso-dilatory, platelet antiaggregation, antiinflammatory, analgesic and antipyretic activity.Said salts are produced by dissolving the sodium salt of the chosen sulphonic acid in distilled water, dissolving the MTA in distilled water to which H.sub.2 SO.sub.4 has been added, reacting together the two solutions to precipitate the MTA sulphonate, and recovering this latter salt with a high degree of purity.

Abstract: New cytidine-diphosphocholine (CDP-choline) salts with long-alkyl chain sulphonic acids suitable for injectable pharmaceutical formulations, but more specifically for oral formulations.Said salts are prepared by a process comprising preparing an aqueous solution of basic CDP-choline, preparing an aqueous sulphonic acid solution, reacting these two solutions together to obtain the required salt, and recovering this salt with a high degree of purity.

Abstract: New carnitine salts with sulphonic acids, of general formula: ##STR1## in which R is a linear or branched alkyl chain of 8 to 18 carbon atoms, and which are particularly suitable for oral use.Said salts are prepared by the following stages:(a) preparing an aqueous solution of carnitine inner salt;(b) preparing an aqueous solution of a sulphonic acid of formula RSO.sub.3 H in which R has the aforesaid meaning;(c) reacting the carnitine inner salt with the sulphonic acid in aqueous solution, and recovering the salt produced by drying the solution.

Abstract: A process is described for the large-scale industrial production of any stable SAMe salt at very high purity and with a yield of about 90% or more.The new process is characterized by the following basic operations: (a) production of yeast containing 12-20 g/kg of SAMe, (b) cell lysis and recovery of the SAMe-rich lysate, (c) ultrafiltration of the lysate, (d) passage through weak acid ion exchange resin, (e) passage through absorption resin, (f) concentration by reverse osmosis, (g) spray-drying the concentrated aqueous solution of SAMe salt.

Abstract: New S-adenosylmethionine (SAM) salts of formula ##STR1## have been prepared in which R, R.sub.1, R.sub.2, m, n and A are as defined in the text.The methods of preparing the new products starting from SAM salts are described.The new products are stable and highly bioavailable, particularly when administered orally.

Abstract: S-adenosylmethionine salts have been prepared which are stable even at elevated temperatures for practically indefinite time periods, and which correspond to the formula ##STR1## in which X is the acid equivalent of a strong mineral acid of pK less than 2.5, and n is 4, 5 or 6.The new salts are practically free from toxicity, and find application in numerous fields of human therapy.

Abstract: New S-adenosylmethionine salts have been prepared which are stable indefinitely with time, even at elevated temperatures.The new salts correspond to the formula: ##STR1## in which X is the equivalent of an organic sulphonic acid of pK less than 2.5,and possess therapeutic activity in numerous fields of human therapy.

Abstract: Therapeutic composition of anti-inflammatory, analgesic and antipyretic activity comprising as its active principle at least one component of general formula: ##STR1## in which: R is a linear or branched alkyl radical of 1-18 C atoms, or phenylalkylene in which the alkylene chain has 1-6 C atomsR.sub.1 is H, an aliphatic acyl radical of 1-6 C atoms or an aromatic acyl radicalR.sub.2 is H, an aliphatic acyl radical of 1-6 C atoms, or an aromatic acyl radical, or alternatively the radicals R.sub.2 together form an isopropylidene chainn is 0 or 1.

Abstract: Therapeutic composition of antiinflammatory, analgesic and antipyretic activity comprising as its active principle at least one component of general formula: ##STR1## in which: R is a linear or branched alkyl radical of 1-18 C atoms, or phenylalkylene in which the alkylene chain has 1-6 C atomsR.sub.1 is H, an aliphatic acyl radical of 1-6 C atoms or an aromatic acyl radicalR.sub.2 is H, an aliphatic acyl radical of 1-6 C atoms, or an aromatic acyl radical, or alternatively the radicals R.sub.2 together form an isopropylidene chainn is 0 or 1.